Manuscript – Forny et al.

# Integrated multi-omics reveals anaplerotic insufficiency in methylmalonyl-CoA mutase deficiency

4

5 Patrick Forny<sup>1a</sup>, Ximena Bonilla<sup>2ab</sup>, David Lamparter<sup>3,8ab</sup>, Wenguang Shao<sup>4,8ab</sup>, Tanja Plessl<sup>1</sup>, Caroline

6 Frei<sup>1</sup>, Anna Bingisser<sup>1</sup>, Sandra Goetze<sup>4,8</sup>, Audrey van Drogen<sup>4,8</sup>, Keith Harshman<sup>3,8</sup>, Patrick G. A.

7 Pedrioli<sup>4,7,8,9</sup>, Cedric Howald<sup>3</sup>, Martin Poms<sup>10</sup>, Florian Traversi<sup>1</sup>, Sarah Cherkaoui<sup>1</sup>, Raphael J.

8 Morscher<sup>1</sup>, Luke Simmons<sup>5</sup>, Merima Forny<sup>1</sup>, Ioannis Xenarios<sup>6,8</sup>, Ruedi Aebersold<sup>7,8</sup>, Nicola

9 Zamboni<sup>7,8</sup>, Gunnar Raetsch<sup>2</sup>, Emmanouil Dermitzakis<sup>3,8</sup>, Bernd Wollscheid<sup>4,8,9\*</sup>, Matthias R.

10 Baumgartner<sup>1\*</sup>, D. Sean Froese<sup>1\*</sup>

- 11
- <sup>1</sup> Division of Metabolism, University Children's Hospital Zurich and Children's Research Center,
- 13 University of Zurich, Switzerland
- <sup>2</sup> Biomedical Informatics, Department of Computer Science, Swiss Federal Institute of Technology /
   ETH Zürich, Switzerland
- <sup>3</sup> Health 2030 Genome Center, Geneva, Switzerland
- <sup>4</sup> Institute of Translational Medicine, Department of Health Science and Technology, Swiss Federal
- 18 Institute of Technology / ETH Zürich, Switzerland
- <sup>5</sup> Division of Child Neurology, University Children's Hospital Zurich, University of Zurich,
- 20 Switzerland
- 21 <sup>6</sup> Agora Center, Rue du Bugnon 21, Lausanne, Switzerland
- <sup>7</sup> Institute of Molecular Systems Biology, Department of Biology, Swiss Federal Institute of
- 23 Technology / ETH Zürich, Switzerland
- 24 <sup>8</sup> PHRT Swiss Multi-OMICS Center / smoc.ethz.ch, Switzerland
- 25 <sup>9</sup> Swiss Institute of Bioinformatics, Lausanne, Switzerland
- <sup>10</sup> Division of Clinical Chemistry, University Children's Hospital Zurich, University of Zurich,
- 27 Switzerland
- 28
- <sup>a</sup> These authors contributed equally to this study.
- 30 <sup>b</sup> These authors are listed alphabetically.
- 31 \* Correspondence: <u>sean.froese@kispi.uzh.ch</u> (Lead Contact), <u>matthias.baumgartner@kispi.uzh.ch</u>,
- 32 <u>bernd.wollscheid@hest.ethz.ch</u>
- 33
- 34

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

## 35 Abstract

36 Multi-layered omics approaches can help define relationships between genetic factors, biochemical 37 processes and phenotypes thus extending research of inherited diseases beyond identifying their 38 monogenic cause<sup>1</sup>. We implemented a multi-layered omics approach for the inherited metabolic 39 disorder methylmalonic aciduria (MMA). We performed whole genome sequencing, transcriptomic 40 sequencing, and mass spectrometry-based proteotyping from matched primary fibroblast samples of 41 230 individuals (210 affected, 20 controls) and related the molecular data to 105 phenotypic features. 42 Integrative analysis identified a molecular diagnosis for 84% (177/210) of affected individuals, the 43 majority (148) of whom had pathogenic variants in methylmalonyl-CoA mutase (MMUT). Untargeted 44 analysis of all three omics layers revealed dysregulation of the TCA cycle and surrounding metabolic pathways, a finding that was further corroborated by multi-organ metabolomics of a hemizygous 45 46 Mmut mouse model. Integration of phenotypic disease severity indicated downregulation of 47 oxoglutarate dehydrogenase and upregulation of glutamate dehydrogenase, two proteins involved in 48 glutamine anaplerosis of the TCA cycle. The relevance of disturbances in this pathway was supported 49 by metabolomics and isotope tracing studies which showed decreased glutamine-derived anaplerosis 50 in MMA. We further identified MMUT to physically interact with both, oxoglutarate dehydrogenase 51 complex components and glutamate dehydrogenase providing evidence for a multi-protein metabolon 52 that orchestrates TCA cycle anaplerosis. This study emphasizes the utility of a multi-modal omics 53 approach to investigate metabolic diseases and highlights glutamine anaplerosis as a potential 54 therapeutic intervention point in MMA.

55

56

57 Take home message: Combination of integrative multi-omics technologies with clinical and
58 biochemical features leads to an increased diagnostic rate compared to genome sequencing alone and
59 identifies anaplerotic rewiring as a targetable feature of the rare inborn error of metabolism
60 methylmalonic aciduria.

Anaplerotic insufficiency in MMA

Manuscript - Forny et al.

# 61 Graphical abstract



62

63

# 64 Keywords

65 Rare disease, inborn error of metabolism, multi-omics, RNA-seq, WGS, proteomics, methylmalonic

66 aciduria

Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

# 68 Main

Inborn errors of metabolism (IEMs), first described by Archibald Garrod<sup>2</sup>, are inherited diseases 69 70 resulting in inadequate function of metabolic proteins. IEMs represent a group of nearly 1,500 71 diseases with a combined incidence of approximately 1:800 births. They present a clinically and 72 genetically heterogeneous picture making them inherently difficult to diagnose <sup>3,4</sup>. Beyond their 73 diagnostic challenges, the pathomechanisms of many IEMs are not well understood, hence most IEMs 74 lack rationalized treatment approaches <sup>5</sup>. 75 Technological advances in genomics and mass spectrometry, leveraging datasets of whole molecule classes (omics), have recently led to a paradigm shift in their use as diagnostic tools. For example, 76 single-layer whole genome sequencing has achieved diagnostic rates of 30-50% in rare disease 77 cohorts <sup>6-8</sup>, while dual-layer combination with RNA sequencing can improve this by 10-35% <sup>9-12</sup>. In 78 79 spite of these advances a significant number of patients remain undiagnosed and disease course 80 prediction remains poor, mainly due to a lack of pathomechanistic understanding and often unclear 81 genotype-phenotype relationships. 82 Multi-layered omics data have the potential to not only increase diagnosis rates of inborn errors of metabolism, but also to uncover novel mechanistic insights into disease pathophysiology<sup>1</sup>, thus 83 84 potentially indicating new therapeutic targets. Such a combinatorial approach is key to move beyond 85 the traditional "one gene – one disease" view of these disorders which fails to explain phenotypic 86 heterogeneity based on genetic variation only. However, simultaneous application of multi-omics 87 technologies for this purpose have not been rigorously tested, and their true utility as well as 88 bottlenecks and knowledge gaps to using them in this regard remain unknown. 89 Here, we have generated multi-layered omics information from individuals suspected with the 90 prototypic IEM methylmalonic aciduria (MMA). MMA has approximately 20 potential monogenic 91 causes most of which result in deficiency of the methylmalonyl-CoA mutase (MMUT) enzyme due to loss of function or proper cofactor (cobalamin) assembly <sup>13</sup>. Even though the (dys)function of MMUT 92 has been studied extensively <sup>14–17</sup>, the main metabolic disturbances in MMA remain an open question. 93

## Anaplerotic insufficiency in MMA

Manuscript - Forny et al.

94	By combining whole genome sequencing (WGS), whole transcriptome sequencing (RNA-seq) and
95	proteotyping information (DIA-MS) with phenotypic features we identified disease causative and
96	pathogenic features in a cohort of MMA affected individuals. We revealed underlying damaging
97	variants and differentially expressed transcripts and proteins directly related to anaplerosis of the TCA
98	cycle. Moreover, follow-up studies utilizing untargeted metabolomics and [U-13C]glutamine tracing
99	revealed a depletion of TCA cycle metabolites and decreased oxidation of glutamine-derived carbons
100	in line with the identified dysregulation of glutamate dehydrogenase and oxoglutarate dehydrogenase
101	enzymes, which we found to physically interact with MMUT. Beyond unveiling these metabolic
102	disturbances in MMUT deficiency, our findings enable a better biological understanding of TCA
103	cycle anaplerosis. Furthermore, the anaplerotic TCA cycle insufficiency may be a potential
104	intervention point in MMA to therapeutically compensate for the loss of TCA cycle intermediates.

Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

## 106 **Results**

## 107 Monogenic disease variant detection through multi-omics

108 To extend the understanding of MMA from the causative genomic lesions to the affected biochemical 109 processes, we performed high-quality WGS, RNA-seq and DIA-MS based proteotyping on fibroblasts 110 taken from 230 individuals (210 affected by MMA, 20 unaffected), representing a mainly European 111 cohort collected over a 25-year period (Fig. 1a and Extended data Fig. 1). Classical MMA is caused 112 by defective processing of methylmalonyl-CoA in the catabolism of propionate, resulting from 113 deficiency of the enzyme methylmalonyl-CoA mutase (MMUT) or proteins related to production of 114 its cofactor adenosylcobalamin (e.g., MMAA, MMAB) or substrate (Fig. 1a). Biochemical assay of propionate incorporation (PI)<sup>18</sup>, and MMUT enzyme activity<sup>14</sup> strongly correlated across all samples 115 116 (rho=0.73, p<0.0001) (Extended data Fig. 2a). Fibroblasts from 150 individuals with MMA had 117 reduced MMUT activity (MMUT-deficient), including 123 which did not increase upon cofactor 118 supplementation (Extended data Fig. 2b, c), while those of 60 individuals had MMUT activity 119 similar to controls (other MMA) (Fig. 1b). 120 In the MMUT-deficient samples we searched the WGS dataset for disease-causing variations in the 121 MMUT gene and identified the molecular cause of disease in 148/150 individuals (Extended data 122 Table 1). Pathogenic variants constituted 165 missense alleles, 105 truncating alleles, 21 splicing alleles, two alleles with in-frame deletions and three alleles containing copy number variants (Fig. 1c, 123 d and Extended data Fig. 2d), of which 41 variants were novel (Extended data Table 1). RNA-seq 124 125 identified reduced MMUT RNA expression in cells from MMUT-deficient individuals compared to 126 the other groups (Fig. 1e). Individuals with strongly reduced RNA expression were enriched for splicing and/or truncating variants, consistent with nonsense-mediated decay (Extended data Fig. 127 128 2e). DIA-MS based proteome measurements revealed reduced MMUT protein levels in MMUT-129 deficient primary fibroblasts (Fig. 1f) which was distributed across all variant types (Extended data 130 Fig. 2e). Consistent with its disease-causing role, MMUT RNA and protein levels were positively and 131 significantly associated with PI and MMUT activity (Extended data Fig. 2f) and MMUT represented

Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

- 132 the most significantly dysregulated RNA and protein of MMUT-deficient samples when compared
- against all other samples (Fig. 1g and Extended data Fig 2g).
- 134 In the remaining 60 samples, we identified bi-allelic disease-causing variants for 22 individuals in
- 135 genes other than MMUT: ACSF3 (17 individuals) (Fig. 1h), TCN2 (3 individuals), SUCLA2 (1
- 136 individual), and MMAB (1 individual) according to the ACMG classification (Extended data Table
- 137 1). By searching RNA-seq for aberrantly expressed genes using OUTRIDER <sup>19</sup> (Extended data Fig
- 138 3), we identified two individuals with very low ACSF3 expression; two with aberrant SUCLA2
- 139 expression, in whom we confirmed predicted splicing and copy number variants at the genomic level
- 140 (Extended data Table 1); two with very low *MMAA* expression, confirmed by complementation
- 141 analysis; and one with low *MMAB* transcript, also confirmed by complementation analysis. Therefore,
- 142 we identified a molecular cause for 29/60 remaining individuals (48%), including 18 pathogenic
- 143 mutations, of which 10 were novel (Extended data Table 1). In sum, we found a diagnosis for
- 144 177/210 (84%) affected individuals (Fig. 1i), including 150 with deficiency of MMUT and 19 with
- 145 damaging variants in ACSF3 accounting for the largest cohort of ACSF3 deficiency.
- 146

#### Anaplerotic insufficiency in MMA

Manuscript – Forny et al.



149 Fig. 1: Multi-facetted omics view enabled a molecular diagnosis in 84% of individuals. a. Study 150 overview with depiction of the propionate pathway including its precursors and the pathways 151 catalyzed by MMUT. b, MMUT enzyme activity per study sub cohort. c, Lollipop plot of all 152 pathogenic variants found on the MMUT gene. d, Proportions of variant types as identified on the 153 MMUT gene. e, Transcript levels of MMUT by study sub cohorts. f, MMUT protein levels divided in study sub cohorts. g, Gene ranks according to p-values as calculated by gene-wise Welch's t-test in 154 155 the proteomics and transcriptomics data. h, Lollipop plot of pathogenic variants identified in ACSF3. 156 i, Proportions of affected genes identified in the whole cohort.

157

## 158 Phenotypic description and association to disease severity

159 It was our expectation that the genetic underpinnings identified above would only partly predict the

160 clinical and biochemical phenotypes of affected individuals. We therefore aimed at establishing a

161 quantitative assessment of disease severity by converting the catalogue of mostly semantic phenotypic

- 162 traits into key numeric variables. A correlation matrix of all phenotypic variables (n = 105), spanning
- 163 clinical symptoms at presentation and during disease course (n = 53), clinical treatments and
- 164 therapeutic response (n = 23), clinical chemistry of blood or tissues including metabolite
- 165 measurements (n = 13), and *in vitro* biochemical parameters (n = 13), revealed a cluster of features
- 166 (MMUT activity, PI) that showed strong correlation across many variables (**Fig. 2a**, **b**).

#### Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

167 Since the identified few variables strongly associated with many clinical features, we postulated that 168 most disease characteristics might be well predicted by one or a select few variables. As proof-of-169 principle, we established a clinical severity score (CSS), which incorporated the outcome of five 170 typical clinical features <sup>20</sup> (for composition see **Methods**), whereby a score of 0 represented absence 171 of these typical MMA features, a score of 1 mild MMA, and a score of 2 or higher (max. 5) moderate 172 to severe MMA disease. Comparison of the CSS against all phenotypic parameters demonstrated 173 significant correlation with 54 individual variables (Fig. 2c), including many classical phenotypic 174 symptoms of MMAuria, such as acidosis, hyperammonemia and muscular hypotonia as well as the requirement for dietary and pharmacological interventions (Extended data Fig. 4a). Importantly, the 175 176 CSS also inversely correlated with age of onset (Extended data Fig. 4b), a parameter that on its own has been used as an indication of clinical severity <sup>21</sup>. 177 178 Multiple correlation analysis identified PI in the presence of hydroxocobalamin (PI+) to significantly 179 correlate to 41 phenotypic features, the most of any individual continuous variable (Fig. 2c). This 180 contrasts, for example, to age at onset which significantly correlated with only 17 parameters (Fig. 181 2c). Closer inspection revealed PI+ to be inversely correlated to disease severity, including significant 182 positive correlation with, e.g., glomerular filtration rate or age at disease onset, and negative correlation with, e.g., methylmalonic acid concentration in plasma, presence of clinical interventions 183 such as protein restriction and the CSS (Fig. 2d and Extended data Fig. 4c, d). Therefore, in line 184 with its validity as a diagnostic test for MMA<sup>18</sup>, the PI+ variable was used as an approximation of 185 186 clinical disease severity in this study.

#### Anaplerotic insufficiency in MMA

Manuscript – Forny et al.



#### 188

189 Fig. 2: Phenomics analysis reveals two main surrogate markers of disease severity (clinical 190 severity score and PI+ activity). a, Correlation matrix of all continuous numeric and discrete phenotype variables. **b**, Number of phenotypic traits according to five phenotype subcategories. **c**, 191 192 Panel of selected phenotypic traits and their overall strength of representing the entirety of the 193 phenomics dataset (here termed clinical disease severity) as assessed by linear modelling. Each point 194 represents the result of linear regression against one other phenotypic variable with the effect size on 195 the y-axis and the resulting p-value on the x-axis. The horizontal curved line indicates the density of data points as distributed along the x-axis. Vertical dashed line indicates threshold of significance (p-196 197 value <0.05). **d**, Linear regression results of the PI+ activity variable compared against the rest of the 198 phenotypic variables. Phenotypic traits available from Source data Table 1.

199

## 200 Multi-layered biology reveals disruption of TCA cycle and associated pathways

- 201 To identify disease-associated expression alterations of genes, proteins, and pathways, we attempted a
- 202 global assessment of transcript and protein expression, integrated with the quantitative phenotype
- 203 variables identified above. Since patients with TCN2, SUCLA2 and ACSF3 deficiency lack most of
- 204 the typical signs and symptoms of classical MMA, we compared MMUT-deficient with all non-
- 205 MMUT-deficient samples (control).
- 206 Investigation of transcripts and proteins using differential correlation patterns (Pearson correlation
- 207 method), dimensionality reduction via Principal Component Analysis and DESeq2 did not
- 208 immediately yield clear grouping of the data, nor obvious expression pattern differences between the
- 209 groups (Extended data Fig. 5a, b, c). However, multi-omics factor analysis <sup>22</sup>, integrating both

#### Anaplerotic insufficiency in MMA

Manuscript - Forny et al.

210	genetic data layers and proteotyping data, identified mitochondrial metabolic pathways and in
211	particular the electron transport chain and the TCA cycle to be enriched in MMUT-deficient samples
212	(Fig. 3a). In more detail, the proteins SLC16A3, CS, MDH2, and OGDH were found to be the main
213	drivers of this particular factor's variance in the proteotyping data within the TCA-associated gene
214	sets (Fig. 3b). Linear discriminant analysis of genes shared between transcriptomics and proteotyping
215	indicated MMUT as the strongest and SUCLA2, OGDH, and PDHB to be top drivers of separation
216	between MMUT-deficient and control samples (Fig. 3c). Further, gene set enrichment analysis
217	utilizing sample stratification by disease severity, both by CSS and PI+, also identified oxidative
218	phosphorylation and the TCA cycle as over-represented pathways in the proteomics (CSS and PI+)
219	and transcriptomics (CSS) datasets (Fig. 3d).
220	The biological relevance of these changes was confirmed in a hemizygous mouse model of MMA $^{23}$
221	(Fig. 3e). Untargeted metabolomics of brain, heart, kidney, liver, plasma, and urine confirmed
222	elevated levels of the eponymous metabolite methylmalonic acid in mutant animals, while pathway
223	enrichment analysis pointed to dysregulated TCA cycle pathways in all tissues and urine (Fig. 3f).
224	Transcriptomics of brain tissue further confirmed the expected 50% reduction in Mmut transcript of
225	mutant mice, along with enrichment of electron transport chain and oxidative phosphorylation
226	pathways (Fig. 3g and Extended data Fig. 6).
227	

#### Anaplerotic insufficiency in MMA

Manuscript – Forny et al.



228

229 Fig. 3: Untargeted integration of omics data layers highlights the TCA cycle and associated 230 pathways as well as oxidative phosphorylation gene sets to be dysregulated in MMA. a, Gene set 231 enrichment test using the multi-omics factor analysis tool (MOFA). b, Detailed feature statistics of the 232 top enriched gene sets following MOFA in the proteomics data. c, Linear discriminant model (split to assign training and test data: 0.5) of transcripts separates MMUT-deficient from control driven by 233 MMUT and other genes related to the TCA cycle. d, Gene set enrichment analysis based on effect size 234 235 ranking derived from differential expression analysis (also see Fig 4b). e. Breeding scheme of Mmut deficient mice. f, Untargeted metabolomics in mouse tissues and body fluids, depicting boxplots for 236 237 methylmalonic acid and metabolite set enrichment analysis based on the complete metabolomics dataset. g, RNA-seq on mouse brain tissue. Boxplots of the relative Mmut transcript abundance and 238 239 gene set enrichment analysis following DESeq2 analysis, dot size represents number of genes per set. 240

### 241 MMUT deficiency leads to transcript and protein alterations in proximal

- 242 enzymes
- 243 Since both data-driven and phenotypically stratified analyses indicated TCA and associated pathways
- to be disrupted in disease, we performed a concerted investigation of the TCA cycle enzymes,
- 245 including those which metabolize anaplerotic (replenishing TCA cycle intermediates) and cataplerotic
- 246 (removing TCA cycle intermediates) reactions, from which we had both RNA and protein

Anaplerotic insufficiency in MMA

Manuscript - Forny et al.

247	information. As controls we included isoforms of TCA enzymes which are not involved in these
248	pathways (Fig. 4a). Direct comparison of RNA and protein expression between MMUT-deficient and
249	control cells revealed MMUT to be significantly dysregulated (Fig. 4a outer band).
250	Differential expression analysis, performed using a linear mixed modelling approach <sup>24</sup> , identified the
251	comes with the strengest effect size and significance to be enriched for mitechandrial localization as
231	genes with the strongest effect size and significance to be enriched for inflociondrial localization, as
252	listed in MitoCarta 3.0 <sup>25</sup> (Extended data Fig. 7a). Closer examination (Fig. 4a middle band, b),
253	identified MMUT to be significantly downregulated in disease at both the RNA and protein level,
254	while ALDH2, which catalyzes the interchange between methylmalonate and methylmalonate
255	semialdehyde, was in contrast upregulated in both. A further upregulated transcript was PDK4 (Fig.
256	<b>4b</b> ), which is responsible for the phosphorylation and as a consequence inactivation of the pyruvate
257	dehydrogenase complex. However, the proteins with the overall largest effect size were OGDH
258	(downregulated in disease) and GLUD1 (upregulated in disease), both enzymes involved in the
259	anaplerosis of glutamine (Fig. 4b).
260	Examination of RNA-protein expression correlation in all samples revealed a limited Spearman
261	correlation of 0.14 at the gene level (4318 transcript-protein pairs) and 0.40 at the sample level (Fig.
262	4c and Extended data Fig. 8a), similar to findings by others <sup>26</sup> . Comparison of RNA-protein
263	correlation in MMUT-deficient cells compared to controls revealed that, while 1158 pairs (26.8%)
264	correlated significantly (p-value < 0.05) in both genotypes (Fig. 4d all colored points and Extended
265	data Fig. 8b) in accordance with previous studies <sup>27</sup> , the correlation of some genes segregated
266	depending on the genotype (MMUT-deficient vs control) (Fig. 4d). In particular, OGDH, GLUD1,
267	CS, and GLS showed higher RNA-protein correlation in MMUT-deficient samples than controls,
268	while SUCLA2 had reduced RNA-protein correlation (Fig. 4a, d and Extended data Fig. 8c). OGDH
269	and SUCLA2 were among the genes with the strongest genotype-dependent RNA-protein correlation
270	changes (Fig. 4d). Interestingly, we found poor RNA-protein correlation for MMUT in both control
271	and MMUT-deficient cells (Fig. 4a, d and Extended data Fig. 8c).
272	Finally, MMUT protein levels positively correlated to protein levels of many TCA and anaplerotic

273 enzymes in control but not in MMUT-deficient cells, while there was little or no protein expression

Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

274 correlation between MMUT and non-TCA protein isoforms in either genotype (Fig. 4a center and Extended data Fig. 8d). Such a relationship is exemplified by MMUT:ACO2 and MMUT:ACO1 275 (Fig. 4a center and Extended data Fig. 8e) and provides the first indication that MMUT may be part 276 of a so far unknown interaction network with these mitochondrial TCA cycle and anaplerotic enzymes 277 278 <sup>28</sup>. Examination of pairwise correlation between all proteins and transcripts (Extended data Fig. 8f, g) in these pathways suggests that TCA cycle and anaplerotic enzymes have a positive correlation 279 with each other, which is not altered in MMUT deficiency, unless MMUT is included in the 280 281 comparison. Overall, the above findings suggest that disruption of MMUT RNA and protein

282 expression drives regulatory changes in certain TCA and anaplerotic enzymes.



283

284 Fig. 4: Transcript-protein and protein-protein correlation analyses reveal coordinated relationships between MMUT and TCA genes and proteins but not their isoforms. a, Circos plot 285 286 depicting raw fold changes of transcripts and proteins, effects sizes derived from differential expression analysis, transcript-protein correlations, and correlative relationships of the MMUT protein 287 288 to TCA proteins and their corresponding isoforms. **b**, O-O and volcano plots illustrate the results of 289 the differential expression analysis based on a linear mixed modeling approach applied to the 290 proteomics and transcriptomics data, restricted to enzymes (or their encoding genes) localized in the 291 mitochondria. c, Histograms of Spearman correlations across 4318 transcript-protein pairs (left), and 292 221 samples (right). d, Scatter plot of Spearman correlations in MMUT-deficient against control. 293 Euclidean distance from the diagonal is calculated based on the formula (MMUT def. correlation -294 control correlation)|/sqrt(2).

#### Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

295

## 296 Metabolomics highlights rewiring of TCA cycle anaplerosis

297 To examine the functional consequences of the above RNA and protein expression alterations, we 298 performed untargeted metabolomic analysis on a set of 6 MMUT-deficient and 6 control primary 299 fibroblasts derived from unaffected individuals (for selection criteria, see Extended data Fig. 9a and 300 Methods). Among the most significantly changed metabolites we found decreased glutamine and 301 alanine as well as increased hexoses, methylcitrate, oxoadipate, aminoadipate, and pyruvate (Fig. 5a). 302 Combining these alterations with observed changes in RNA and protein expression in the same 303 samples provides insight into disruption of TCA cycle anaplerosis in MMUT deficiency (Fig. 5b). 304 The increased pyruvate level (Fig. 5a, c), increased expression of the PDH complex inhibitor PDK4 305 (Fig. 4b), and strongly elevated 2-methylcitrate (Fig. 5c), a biomarker of MMA formed by citrate 306 synthase mediated mis-condensation of oxaloacetate with propionyl-CoA instead of acetyl-CoA, 307 together suggest reduced incorporation of pyruvate into the TCA cycle. This is further supported by 308 the analysis of our cross-dimensional data which identified stronger pyruvate to PDHB transcript and 309 pyruvate to PDHX protein correlations (Fig. 5d), implying reduced pyruvate turnover per transcript 310 and protein respectively. Consecutive metabolites in a pathway often correlate strongly <sup>27</sup>, here 311 exemplified by malate and fumarate (Fig. 5d). Although we found such a correlation between 312 pyruvate and its downstream metabolite (iso)citrate in both control and MMUT-deficient cells, our 313 data suggests that in MMUT-deficient cells a higher concentration of pyruvate is required to create the 314 same amount of (iso)citrate as controls (Fig. 5d), again supporting reduced incorporation of pyruvate 315 into the TCA cycle. 316 Despite this reduced pyruvate-mediated anaplerosis, 2-oxoglutarate, succinate, fumarate and malate

317 levels remained unchanged in MMUT-deficient cells (Fig. 5c and Extended data Fig. 9b),

318 suggesting stable TCA cycle metabolite pools in these primary fibroblast cells. As our previous

319 findings indicated altered proteins in glutamine anaplerosis (Fig. 3b, c, 4a), we investigated the

320 contribution of this pathway towards the balance of the TCA cycle. Glutamine strongly correlated

#### Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

321 with glutamate in both MMUT-deficient and control samples (Fig. 5d). However, in MMUT-deficient 322 cells, glutamine and glutamate were decreased (Fig. 5c), and there was a negative correlation of glutamate with 2-oxoglutarate, suggestive of more tightly regulated glutamine flux under disease 323 conditions (Fig. 5d). Abrogated positive correlation of glutamate and aspartate potentially points to an 324 325 altered dependence on glutamate for TCA cycling but not production of cataplerotic metabolites, such as aspartate (Fig. 5d). In line with this, we found an inverse relationship between MMUT transcript 326 327 and 2-oxoglutarate in MMUT-deficient cells (Fig. 5d). While we focused our efforts on the 328 investigation of TCA anaplerosis at this stage, the power of our untargeted dataset was further illustrated by more unexpected findings, including increased oxoadipate and aminoadipate (Fig. 5a), 329 upstream metabolites of 2-oxoadipate dehydrogenase complex which shares its E2 (DLST) and E3 330 331 (DLD) components with 2-oxoglutarate dehydrogenase complex (Extended data Fig. 9c), suggestive 332 of a preference for 2-oxoglutarate over 2-oxoadipate metabolism. 333 The above results point to an adjusted reliance on the glutamine anaplerotic pathway in disease; a 334 hypothesis we tested further by assessing relative carbon incorporation derived from anaplerotic 335 glutamine into TCA cycle and associated intermediates using MS-based stable isotope tracing. For 336 this experiment, control (wildtype, WT), DLST-KO, and MMUT-KO 293T cells, validated by Western 337 blotting and enzyme activity measurements (Extended data Fig. 10), were cultured in glutamine-free glucose-DMEM supplemented with [U-<sup>13</sup>C]glutamine. DLST-KO cells were used as a control to 338 339 mimic the above detected reduction of OGDH protein in MMUT deficiency, allowing us to assess 340 fractional incorporation of glutamine into TCA cycle intermediates when the oxidative pathway 341 (clockwise from 2-oxoglutarate, Fig. 5e) is completely blocked (DLST is a component of the 2-342 oxoglutarate dehydrogenase complex, metabolizing 2-oxoglutarate to succinyl-CoA). By analyzing 343 the pool sizes, we could confirm reduced levels of glutamine and glutamate (Extended data Fig. 11a) 344 comparable to the patient fibroblasts (Fig. 5c), validating our experimental model. In addition, we 345 found markedly reduced TCA cycle metabolites, including citrate, fumarate, malate, succinate, and 346 aspartate (a proxy for oxaloacetate<sup>29</sup>), indicating an overall reduced TCA metabolite pool in MMUT 347 deficiency, while KO of *DLST* led to virtual absence of most TCA cycle metabolites (Fig. 5f). To

Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

348	identify differential labeling patterns, we studied the isotope distribution based on the relative
349	incorporation of glutamine-derived carbons and found a decreased proportional fraction of M+4
350	isotopologues under MMUT-KO conditions for all studied TCA cycle metabolites and aspartate (Fig.
351	5g, Extended data Fig. 11b), suggesting reduced derivation from glutamine. Indeed, we found a
352	decreased fractional contribution of glutamine to the TCA cycle for all studied intermediates (Fig.
353	5h). Moreover, consistent with reduced OGDH activity, there was a relative preference for the
354	reductive TCA cycle pathway, as indicated by an increased M+5/M+4 ratio for citrate <sup>30,31</sup> in MMUT

- 355 deficiency (Extended data Fig. 11c). In sum, this suggests there is reduced production of TCA cycle
- 356 intermediates which is not compensated for by glutamine anaplerosis.



358

Fig. 5: Polar metabolomics in selected patient fibroblasts and glutamine tracing studies in 359 360 CRISPR/Cas9 KO 293T cells highlight differential glutamine anaplerosis. a, Volcano plot depicting differentially expressed metabolites. Highlighted are the ones particularly relevant to this 361 362 study. **b**, Schematic depiction of the TCA cycle and relevant anaplerotic reactions. The color code indicates dysregulations on metabolite and protein level; grey metabolites were not detected. c, 363 Boxplots to compare relevant TCA cycle metabolites, including the pathologically relevant biomarker 364 365 2-methylcitrate formed upon condensation of oxaloacetate with propionyl-CoA. d, Pearson correlation of a certain key metabolite against a metabolite, transcript, or protein variable, e, 366 Schematic representation of labeling of TCA cycle and associated metabolites derived from labelled 367 glutamine via anaplerosis. Circles represent carbon atoms. f, Pool sizes of metabolites in control and 368 369 CRISPR/Cas9 KO 293T cells. g, Relative abundance of isotopologues after glutamine labelling. h, 370 Relative fractional incorporation of labelled glutamine into TCA cycle and associated metabolites. All 371 p-values are calculated by Wilcoxon rank test.

Anaplerotic insufficiency in MMA

#### Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

## 373 MMUT physically interacts with 2-oxoglutarate dehydrogenase and other

## anaplerotic enzymes

375 The above observed adjustments in glutamine anaplerosis have an unclear regulatory etiology. Based on the strong protein expression correlation between MMUT and proximal TCA cycle and anaplerotic 376 enzymes (Fig. 4a and Extended data Fig. 8d), we hypothesized that these proteins may be part of a 377 378 shared metabolon complex, potentially facilitating regulation of TCA cycle anaplerosis of glutamine by protein-protein interactions <sup>28</sup>. To gain insights into this potential physical relationship, we took 379 380 advantage of over-expression of C-terminally flag-tagged versions of MMUT, two pathway members 381 (MMAB and MCEE) expected to participate in any multi-protein complex containing MMUT, and 382 two negative controls (VLCAD and empty vector) in 293T cells (Fig. 6a). Using cross-linking affinity 383 purification coupled to mass spectrometry, at 1.0% FDR using 2 peptides minimum at 95% threshold, 384 each of these 'bait' proteins pulled-down a total of 100-350 different 'prey' proteins over 3 biological 385 replicates (Fig. 6b). Within this intersection, we identified 57 prey proteins pulled down by MMUT, 386 MMAB and MCEE in at least one replicate, but not by empty vector or VLCAD in any replicate (Fig. 387 **6b**).

388 Analysis of variance (ANOVA) of the biological triplicates comparing MMUT with EV and VLCAD

identified 22 proteins to be significantly enriched (nominal p-value <0.05) in the MMUT sample (Fig.

390 6c and Extended data Table 2). All proteins were designated by Uniprot to have mitochondrial

391 localization and included GLUD1, GOT2 and DLST (Fig. 6c). ANOVA comparing the intersection of

392 proteins confidently pulled down by all three of MMUT, MMAB and MCEE but not of EV or

393 VLCACD identified 11 MMUT/MMAB/MCEE interacting proteins, including GLUD1 and GOT2;

394 while the intersection of two of MMUT, MMAB, and MCEE against both negative controls identified

395 13 proteins which interacted with MMUT/MMAB, MMUT/MCEE or MMAB/MCEE, including

396 DLST (Fig. 6d and Extended data Table 2). Interaction of MMUT and DLST was further confirmed

397 by Western blot analysis (Fig. 6e and Extended data Fig. 12ab). These data indicate that MMUT

398 physically interacts with GLUD1 and the oxoglutarate dehydrogenase complex component DLST and

399 suggests that disruption of this interaction may underlie their altered regulation in disease.

Anaplerotic insufficiency in MMA

Manuscript - Forny et al.

#### 400



401

#### 402 Figure 6. MMUT interacts physically with GLUD1, DLST, and GOT2 as demonstrated by

403 FLAG-tag pull-down. a, Outline of experimental and control groups indicating which protein was

404 used with a FLAG-tag in a cross-linking affinity purification experiment coupled to subsequent

405 analysis of the pull-down samples by mass spectrometry. **b**, Venn diagram of proteins pulled down by

406 the different flag-tagged proteins. c, ANOVA p-values of all proteins pulled down by MMUT. Blue

407 dots indicate proteins with mitochondrial location according to Uniprot. **d**, Interaction network of

408 significantly enriched proteins (ANOVA p-value < 0.05). Thicker connector indicates lower p-value.

409 e, Western blot of immunoprecipitation of flag-tagged MMUT probing for DLST.

Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

# 411 **Discussion**

412 In this study, we used an integrated multi-modal approach to diagnose and uncover new

413 pathomechanisms of the inborn error of metabolism MMA. Unique to this investigation was the large

414 set of patient samples along with corresponding phenotypes available, and the ability to coordinate

415 aliquots from the same samples to generate data at three molecular layers. The results of our study

416 will encourage future endeavors to use our approach in any setting of an inborn monogenic disease.

417 Moving forwards, the datasets derived from our study can be further exploited, e.g., by applying

418 network contextualization tools <sup>32</sup>, integrating multi-omics and flux modeling <sup>33</sup>, and reconstructing

419 genome-scale metabolic networks <sup>34</sup>, continuing to refine the pipeline of a multi-modal study of

420 inborn errors of metabolism.

421 Our findings reinforce the value of comprehensive and complementary datasets to increase diagnostic 422 yield and the understanding of the pathophysiological underpinnings of disease. Our multi-modal 423 profiling allowed the identification of causative genetic variation in 84% of the cohort, including 424 causative factors in the samples without MMUT deficiency. We were able to widen the set of genes beyond the classical MMA genes MMUT, MMAA, and MMAB. For example, the identification of 425 ACSF3 damaging variants in our cohort is particularly interesting as they have recently been linked to 426 combined malonic and methylmalonic aciduria (CMAMMA)<sup>35</sup>. The phenotype of CMAMMA 427 patients was indistinguishable from the remainder of MMA patients with normal MMUT activity, 428 429 highlighting the fact that inborn errors of metabolism present with widely overlapping phenotypes and 430 that they should be studied with large gene panels or with WGS approaches to avoid biases towards known genes and to augment the chances of diagnosis. 431

432 While the ability of clinical phenotypic information to predict a molecular diagnosis was limited,

433 phenotypic variables – both clinical and biochemical – enabled sample stratification by disease

434 severity and consequently identification of multi-level alterations of metabolic genes/proteins which

435 were not apparent following examination of single omics layers. Such a move away from "data silos"

436 into true integrative and mechanism-based multi-layered analysis remains challenging, as it requires

437 new analytical and statistical methods to combine these disparate data sets <sup>36</sup>. In this capacity, multi-

#### Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

omics factor analysis <sup>22</sup> highlighted the disruption to transcripts and proteins of the TCA cycle and 438 439 related pathways, a finding verified by the correlation with phenotypic data utilizing both propionate incorporation activity and a clinical severity score. Following multi-modal integration, we performed 440 metabolomics in select patient cells and further complemented the data with glutamine tracing and 441 442 protein-protein interaction studies in a second cell model. In sum, these experiments showed decreased TCA metabolite pools and a reduced glutamine-derived anaplerosis, in line with the 443 detected reduction of OGDH. In addition, we identified a list of novel MMUT-interaction candidates, 444 445 among which DLST (OGDH complex component) and GLUD1 are directly involved in the glutamine 446 anaplerotic pathway. Abrogation of the interaction with MMUT, due to MMUT knockout, could explain the reduction of glutamine anaplerosis. It is of note, that such a tailored set of follow-up 447 448 experimental approaches – orthogonal to multi-omics data – is invaluable for molecular assessment of 449 potential targets and the validation of their biological significance. 450 Overall, our results highlight the importance of the loss of methylmalonyl-CoA as an anaplerotic 451 source and indicate a relevant reduction of TCA cycle intermediates in MMA, in part due to reduced 452 anaplerotic supply stemming from glutamine. For the first time we show anaplerotic insufficiency in 453 MMA and propose this phenomenon as a novel therapeutic target. Anaplerotic stimulating approaches 454 have precedent in IEMs, including application of triheptanoin in long-chain fatty acid oxidation disorders <sup>37</sup>. Unfortunately, since fatty acid β-oxidation produces two acetyl-CoA and one propionyl-455 CoA per heptanoate molecule, use of this particular compound in MMUT deficiency is not feasible. 456

457 However, anaplerotic treatment of patients suffering from the MMA-related disorder propionic

458 aciduria with the TCA cycle intermediate citrate has been attempted, with inconsistent results  $^{38}$ .

459 Based on our findings, compounds such as dimethyl oxoglutarate, a membrane-permeable alternative

460 to 2-oxoglutarate, previously used in a model of OXPHOS dysfunction <sup>30</sup>, may represent a more

461 promising therapeutic strategy. Studies to delineate the efficacy of such approaches in preclinical and

462 clinical models will be important for the ongoing development of new treatments for MMA and

463 inborn errors of metabolism in general.

Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

## 465 Acknowledgements

- 466 This project was funded by the ETH domain strategic focus area "Personalized Health and Related
- 467 Technology" (PHRT; <u>https://www.sfa-phrt.ch</u>). This work received financial support from the Swiss
- 468 National Science Foundation [31003A 175779] to M.R.B. and [310030 192505] to D.S.F. and from
- 469 the University Research Priority Program of the University of Zurich (URPP) ITINERARE—
- 470 Innovative Therapies in Rare Diseases. P.F. was supported by the Filling the Gap grant awarded by
- 471 the Medical Faculty, University of Zurich, Switzerland. We acknowledge the Functional Genomics
- 472 Center Zurich of the University of Zurich for RNA sequencing of the mouse brain tissues and
- 473 bioinformatics support as well as for support with the glutamine isotope studies.

474

# 475 Author Contributions

- 476 Conceptualization, I.X., R.A., G.R., E.D., B.W., M.R.B., D.S.F.; Methodology, P.F., X.B., D.L.,
- 477 W.S., T.P., M.F., L.S., C.H., R.J.M., S.C., S.G., A.v.D., K.H., P.P., N.Z.; Investigation/Data analysis,
- 478 P.F., X.B., D.L., W.S., T.P., C.F., A.B., S.C., M.P., S.G., P.P., F.T., N.Z., G.R., D.S.F.; Writing –
- 479 Original Draft, P.F., D.S.F.; Writing Review & Editing, all co-authors; Visualization, P.F., X.B.,
- 480 D.L., W.S., C.F.; Supervision, P.F., K.H., P.P., F.T., I.X., G.R., E.D., B.W., D.S.F.; Project
- 481 Administration, P.F., B.W.; Funding Acquisition, R.A., B.W., M.R.B., D.S.F.

482

# 483 **Declaration of interests**

484 The authors declare no competing interests.

Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

# 486 Extended data

487 Supplementary figures and tables in separate files.

488

# 489 Source data

- 490 Source data Proteomics
- 491 All mass spectrometry proteomics raw files have been deposited to the ProteomeXchange Consortium
- 492 via the MassIVE partner repository (https://massive.ucsd.edu) with the dataset identifier
- 493 MSV000088791.
- 494 Source data Metabolomics
- 495 Metabolomics mass spectrometry raw data for human fibroblast measurements have been uploaded to
- the MassIVE data repository (https://massive.ucsd.edu) with the dataset identifier MSV000089082.
- 497 Source data Affinity capture mass spectrometry raw data
- 498 IP-MS raw files have been deposited to the ProteomeXchange Consortium via the MassIVE partner
- 499 repository (https://massive.ucsd.edu) with the dataset identifier MSV000088791.
- 500 Source data Quantitative Proteomics Data
- 501 CSV file containing the quantitative proteomics data used for the analyses.
- 502 Source data Quantitative Transcriptomics Data
- 503 CSV file containing the quantitative RNA-seq data used for the analyses.
- 504 Source data Table 1 Phenotypic dataset
- 505 CSV file containing all clinical information.

Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

## 506 Source data Table 2 Pull-down

507 Complete list of proteins that were pulled down in the affinity capture mass spectrometry experiment.508

# 509 Methods

- 510 Cohort and patient-derived fibroblast samples
- 511 Primary fibroblast samples and corresponding disease-related information, including clinical and
- 512 diagnostic data, was collected from 1989 to 2015. The information was obtained and used under the
- 513 ethics approval granted by the Ethics Committee of the Canton of Zurich, Switzerland (no. KEK-
- 514 2014-0211, amendment: PB\_2020-00053). Upon collection, primary fibroblasts were cultured using
- 515 Dulbecco's modified Eagle medium (Gibco, Life Technologies, Zug, Switzerland) with 10% fetal
- 516 bovine serum (Gibco) and antibiotics (GE Healthcare, Little Chalfont, UK) and either used
- 517 immediately, or exchanged to 90% fetal bovine serum and 10% dimethyl sulfoxide and stored in
- 518 cryovials under liquid nitrogen. A frozen aliquot of each primary fibroblast cell culture was sent for
- 519 WGS, RNA-seq and DIA-MS analysis (Fig. 1a). RNA-seq and DIA-MS were always performed from
- 520 matched aliquots.
- 521 Clinical disease severity score

522 The clinical disease severity score was based on five typical clinical signs/symptoms of MMA <sup>20</sup>,

- 523 including age at disease onset, as well as the presence of neurological abnormalities, kidney
- 524 impairment, hematological abnormalities, and failure to thrive. Each patient was assigned a score
- 525 from 0-5 indicating increasing disease severity (**Source data Table 1**).

526 Biochemical assays

527 Propionate incorporation into acid precipitable material of primary fibroblasts was assessed according
 528 to a protocol described previously <sup>39</sup> with modification as described <sup>18</sup>. Methylmalonyl-CoA mutase

#### Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

enzyme activity assay was performed in crude cell lysates as originally described <sup>40,41</sup> using recent
 modifications <sup>14</sup>.

## 531 Whole genome sequencing

532 Genomic DNA was isolated using the QIAmp DNA Mini Kit reagents (Qiagen; Hilden, Germany) following the protocol provided by the supplier. DNA was quantified by Qubit (Thermo Fisher; 533 Waltham, USA). Whole genome sequencing libraries were prepared with the TruSeq DNA PCR-free 534 535 library reagents (Illumina; San Diego, USA) using 1ug of genomic DNA following the protocol 536 provided by the supplier. The genomic DNA libraries were quantified using the KAPA Library 537 Quantification Complete Kit (Roche; Basel, Switzerland) according to the protocol supplied with the 538 reagents. The quantified libraries were sequenced on the NovaSeq 6000 sequencer (Illumina) using a 539 150-nucleotide paired end run configuration following the protocol provided by the supplier.

### 540 RNA sequencing

Total RNA was isolated using the RNeasy Plus Mini Kit (Qiagen). The total RNA was quantified using the Qubit (Thermo Fisher) and quality-controlled using the Fragment Analyzer (Agilent, Santa Clara, USA). RNA-seq libraries were prepared using the TruSeq Stranded mRNA-seq reagents (Illumina) using 200ng of total RNA following the protocol provided by the supplier. The quality of the RNA-seq libraries was assessed on Fragment Analyzer (Agilent) and the libraries were quantified using the Qubit (Thermo Fisher). The libraries were sequenced on Illumina HiSeq 4000 using the 75nucleotide paired end run configuration following the protocol provided by the supplier.

## 548 Sample preparation for mass spectrometry proteotyping measurements

549 Samples were processed in blocks of 8 taking into consideration a balance between disease types and 550 control samples. All other factors within a block were randomized. 230 samples were processed in 551 three batches. For sample processing, aliquots of primary fibroblast (~1e6 cells per vial, frozen in 552 either DMEM or FBS or a mix of DMEM/FBS, plus 10% DMSO) were washed twice in ice-cold PBS

#### Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

553	(Gibco). After centrifugation for 5 minutes at 300g, the cells were resuspended in lysis buffer
554	(Preomics) at a ratio of 1:1 (vol pellet/vol lysis buffer) and incubated at 95°C for 10 mins. Samples
555	were sonicated in a vial tweeter (Hielscher Ultrasound Technology) at 4°C for 3 cycles with an
556	amplitude 100%, power 80% during 30 secs. For each sample, the total protein concentration was
557	estimated by nanodrop. 100 ug of protein lysate were further processed with the iST kit (Preomics).
558	The purified peptides were resuspended in LCLoad buffer containing iRT peptides (Biognosys) at a
559	concentration of 1 ug/ul.

560 Spectral library generation

561 For spectral library generation, three times 24 samples (3x8 sample blocks) were pooled. Pooled sample batches were digested as described above. 100 µg of purified peptides were fractionated on a 562 563 C18 column (YMC-Triart, C18, 3µm, 250 x 0.5 mm ID) according to pH on an Agilent HPLC 1260 564 system with a stepped 61 min gradient ranging from 95 % buffer A (20 mM ammonium formate acid/H2O) to 85% buffer B (20 mM ammonium formate/90 % ACN). 48 fractions were collected per 565 566 sample and subsequently pooled to 24 fractions. Samples were resuspended in 5% ACN/0.1% FA and 567 analyzed on a QExactive HF-X mass spectrometer (Thermo Fisher Scientific) in DDA mode. The same nLC 1200 configuration and mobile phase gradient elution conditions as for DIA were applied. 568 Full MS survey scans were acquired at a resolution of 60,000 with automatic gain control (AGC) 569 570 target of 3e6 and a maximum injection time of 45 ms over a scan range of m/z 375-1500. A data-571 dependent top 12 method was used for HCD MS/MS with a normalized collision energy of 28 at a 572 resolution of 15,000 and a fixed first mass of m/z 100. Precursor ions were isolated in a 1.4-Th window and accumulated to reach an AGC target value of 1e5 with a maximum injection time of 22 573 574 ms. Precursor ions with a charge state of 1 and 6 as well as isotopes were excluded for fragmentation. 575 Dynamic exclusion was set to 15s.

576 DDA raw files were processed with Proteome Discoverer (v. 2.2) using a human UniProt database
577 (release 201804) together with iRT peptides (Biognosys) and common contaminants. The processing
578 workflow consisted of SequestHT <sup>42</sup> and Amanda <sup>43</sup> nodes coupled with Percolator <sup>44</sup>. The following

269972; this version posted April 8, 2022. The copyright holder for this preprint medRxiv preprint doi: https://doi.org/10.1101/2022.01.27. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

#### Anaplerotic insufficiency in MMA

586

Manuscript – Forny et al.

579	search parameters were used for protein identification: (i) a peptide mass tolerance of 10 ppm; (ii) an
580	MS/MS mass tolerance of 0.02 Da; (iii) fully tryptic peptide search with up to two missed cleavages
581	were allowed; (iv) carbamidomethylation of cysteine was set as fixed modification, methionine
582	oxidation and protein N-term acetylation were set as variable modifications. Percolator was set at max
583	delta Cn 0.05, with target FDR strict 0.01 and target FDR relaxed 0.05. The spectral library from
584	Proteome Discoverer was imported into Spectronaut v12 (Biognosys, Schlieren, Switzerland) using
585	standard parameters with 0.01 peptide spectrum match (PSM) FDR.

DIA-MS setup and data analysis

- 587 For DIA analysis samples were measured on a Q Exactive HF mass spectrometer (Thermo Fisher
- 588 Scientific). Mobile phase A consisted of HPLC-grade water with 0.1% (v/v) formic acid, and mobile
- 589 phase B consisted of HPLC-grade ACN with 20% (v/v) HPLC-grade water and 0.1% (v/v) formic
- acid. Peptide separation was carried out on an ES806, 2 µm, 100 Å, 150 µm i.d. x 150 mm, C18 590
- 591 EASY-Spray column (Thermo Fisher Scientific) at a temperature of 50°C. For LC-MS/MS analyses,
- 592 2 µg of each sample were loaded onto the column via an Easy-nLC 1200 system (Thermo Fisher
- 593 Scientific). Samples were loaded at 4  $\mu$ L/min with 100% mobile phase A for 5 min. Peptide elution
- 594 was performed using the following gradient: i) 2% to 8% mobile phase B in 4 min, ii) 8% to 32%
- 595 mobile phase B in 49 min, iii) 32% to 60 % mobile phase B in 1 min, and iv) ramp to 98% mobile
- 596 phase B in 1 min at 2  $\mu$ L/min.

597 For DIA-Acquisition on a Q Exactive HF mass spectrometer, we applied a DIA method published elsewhere <sup>45</sup>. In short, we performed an MS1 scan over a mass range of m/z 400-1210 at a resolution 598 599 of 120,000 with an AGC target value of 3e6 and with a maximum injection time of 50 ms. For 600 MS/MS scans, resolution was at 0,000 with an AGC target value of 1e6 and with "Auto" maximum 601 injection time. Precursor ions were isolated within a 15-Th window and fragmented by HCD with 602 normalized collision energy 28. 54 MS/MS scan windows were defined, interspersed every 18 scans 603 with an MS1 scan.

#### Anaplerotic insufficiency in MMA

Manuscript - Forny et al.

604	DIA data Analysis was performed in Spectronaut v12 (Biognosys) using standard parameters. For
004	DIA data Analysis was performed in Spectronaut V12 (Diognosys) using standard parameters. For
605	identification, a Qvalue cut-off of 0.01 was applied on the precursor as well as on the protein level.
606	The MS1 area was selected for quantification. Quantification parameters were set to mean peptide
607	quantity for major group quantity, the top 3 peptides were selected for protein quantity calculation.
608	Data filtering was set to Qvalue sparse, with no imputation. Cross-run normalization was set to local.
609	The protein report for downstream analysis contained information report about PG.ProteinAccessions,

- 610 PG.ProteinDescriptions, PG.ProteinNames. PG.Qvalue and PG.Quantity.
- 611 Selection of primary fibroblasts for polar metabolomics
- 612 To select cell lines for metabolomics, we opted for a balanced design with 10 MMUT deficient cell
- 613 lines and 10 control lines. MMUT deficient lines were picked to show over-expression of GLUD1 and
- 614 under-expression of OGDH whereas the control lines were chosen to show the reverse pattern. We
- 615 fitted a mixed effects model with PI+ as response, two fixed effects for GLUD1 and OGDH
- 616 expression, and a random effect with the same covariance structure as the proteomics data after
- 617 column and row normalization. From the MMUT deficient and control cell lines, we chose 10 with
- 618 the lowest predicted value of PI+ and 10 with the highest predicted value respectively. The top ten
- 619 ranked MMUT deficient (MMA014, MMA92, MMA042, MMA67, MMA93, MMA104, MMA013,
- 620 MMA030, MMA138, MMA036) and the last 10 ranked control primary fibroblasts (MMA219,
- 621 MMA221, MMA227, MMA222, MMA213, MMA230, MMA226, MMA228, MMA225, MMA215)
- 622 were selected and cultured as described above. Four primary fibroblasts in each group did not meet
- 623 growth criteria, most likely due to the long freezing period, and were excluded (MMA014, MMA92,
- MMA042, MMA013, MMA219, MMA221, MMA227, MMA226). Six primary fibroblast lines per
- 625 group were selected for the polar metabolomics experiment.
- 626 Quality assessment of WGS, RNA-seq and DIA-MS data
- 627 Overall quality assurance tests revealed a mean of high-quality aligned genomic reads of  $8.7 \times 10^8$  at a
- 628 median genomic coverage of >38-fold (Extended data Fig. 1b). A median of 3.74 million SNVs

#### Anaplerotic insufficiency in MMA

Manuscript - Forny et al.

629	were called using the Genome Analysis Toolkit <sup>46</sup> and DeepVariant <sup>47</sup> . RNA-seq data showed a
630	median Phred score of >36.3 at three and more cycles (Extended data Fig. 1c), while proteomics data
631	showed a high reproducibility with 2218 proteins detected in at least 75% of samples (Extended data
632	Fig. 1d). For nine of the 230 samples RNA extraction yielded insufficient nucleic acid amounts to
633	proceed with transcriptome sequencing; hence, these datasets were excluded from all further analysis
634	(transcriptomics data of sample IDs 22, 54, 59, 78, 89, 109, 123, 207, 221).

## 635 Fibroblast sample preparation for polar metabolomics

636 100,000 cells per well were seeded in a 6 well plate and grown for 48 hours. Media was removed and

637 cells washed with 2 mL per well of 150 mM ammonium hydrogen carbonate (NH<sub>4</sub>HCO<sub>3</sub>) at pH 7.4

twice. The whole plate was flash-frozen in liquid nitrogen for 20 seconds and then stored at -80°C.

639 Metabolites were extracted by putting the plate on dry ice and adding 400 ul of cold (-20°C) 40:40:20

acetonitrile:methanol:water and incubated at -20°C for 10 minutes. Supernatant was collected. Added

another 400 ul of 40:40:20 acetonitrile:methanol:water and incubated at -20°C for 10 minutes. Plates

642 were put on dry ice and cells were scraped mechanically. The supernatant including the scraped cells

643 were collected in the same tube as during the first extraction step. Collection tubes were centrifuged at

644 13,000 rpm for 2 minutes at 4°C. Supernatants were stored at -20°C prior to metabolomics analysis.

## 645 Polar metabolomics in patient-derived fibroblasts

646 Untargeted metabolite profiling was performed using flow injection analysis on an Agilent 6550

647 QTOF instrument (Agilent, Santa Clara, CA) using negative ionization, 4 GHz high resolution

648 acquisition, and scanning in MS1 mode between m/z 50-1000 at 1.4 Hz <sup>48</sup>. The solvent was 60:40

649 isopropanol:water supplemented with 1 mM NH4F at pH 9.0, as well as 10 nM hexakis(1H, 1H, 3H-

tetrafluoropropoxy)phosphazine and 80 nM taurochloric acid for online mass calibration. The seven

- batches were analyzed sequentially. Within each batch, the injection sequence was randomized. Data
- 652 was acquired in profile mode, centroided and analyzed with Matlab (The Mathworks, Natick).
- 653 Missing values were filled by recursion in the raw data. Upon identification of consensus centroids

#### Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

654 across all samples, ions were putatively annotated by accurate mass and isotopic patterns. Starting 655 from the HMDB v4.0 database, we generated a list of expected ions including deprotonated, fluorinated, and all major adducts found under these conditions. All formulas matching the measured 656 657 mass within a mass tolerance of 0.001 Da were enumerated. As this method does not employ 658 chromatographic separation or in-depth MS2 characterization, it is not possible to distinguish between compounds with identical molecular formula. The confidence of annotation reflects Level 4 but - in 659 practice – in the case of intermediates of primary metabolism it is higher because they are the most 660 661 abundant metabolites in cells. The resulting data matrix included 1809 ions that could be matched to deprotonated metabolites listed in HMDB. All m/z peaks that remained unmatched or were associated 662

to adducts or heavy isotopomers were discarded.

## 664 Mouse care and handling

Ethics approval was obtained prior to the study from the Cantonal Veterinary Office Zurich under the license number 202/2014. Mice were kept under standard conditions, i.e. single-ventilated cages with controlled humidity and room temperature of 22°C. Generation of the *Mmut*-p.Met698Lys variant model and crossing with a *Mmut*-ko/wt model was done as previously described <sup>23</sup>.

669 Harvesting of mouse tissues

670 Urine was collected in the morning after one night in a metabolic cage. The sediment was removed,

and supernatant was flash frozen in liquid nitrogen. Tissue samples were harvested from mice aged 58

to 63 days. Animals were anesthetized by sevoflurane. Portal blood was taken and kept on ice to

673 coagulate, centrifuged at 4°C and snap frozen in liquid nitrogen directly after. Liver, kidneys, heart,

- and brain were harvested and snap-frozen in liquid nitrogen. After the procedure, the mice were
- 675 directly euthanized by cervical dislocation. All samples were stored at -80°C prior to analysis.

#### Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

## 676 Metabolomics in mouse tissues

677 The mouse body fluid and tissue samples derived from five Mmut-ki/wt and five Mmut-ko/ki mice were harvested as described above and prepared as previously published <sup>49</sup>. Sample analysis using 678 liquid chromatography-mass spectrometry was performed as previously published <sup>50</sup>. Ions were 679 annotated to metabolites based on exact mass to the KEGG database <sup>51</sup> considering [M-H+] and 0.01 680 681 Da mass accuracy. Significantly changing ions between mutant and control conditions were identified using a two-sample t-test. Pathway analysis was performed using annotated ion list ranked by p-value 682 significance. Pathway enrichments were calculated using KEGG metabolic pathway definitions and a 683 hypergeometric test. 684

## 685 Transcriptomics in mouse brains

686 Brain tissue samples were harvested as described above. Four mice per genotype groups Mmut-ki/wt

687 and Mmut-ko/ki were used. RNA was purified using DNAse kit (Qiagen, No. 79254) together with

688 QIAmp RNA Blood Mini Kit (Qiagen, No. 52304). RNA-seq reads were aligned with the STAR-

aligner <sup>52</sup>. As reference we used the Ensembl mouse genome build GRCm38. Gene expression values

690 were computed with the function featureCounts from the R package Rsubread  $^{53}$ .

### 691 CRISPR gene-editing experiments

692 CRISPR-Cas9 editing was performed as described <sup>54</sup>. Cas9 protein was provided as a plasmid

693 (PX459-V2.0, Addgene, 62988) and guide RNA as gBLOCKS <sup>55</sup> (IDT Technologies). 293T cells

694 were transfected using the Neon transfection system (Thermo Fisher Scientific) containing 100,000

695 cells, 0.6 μg of Cas9 plasmid and 600 ng of guide RNA following manufacturer's instructions. 48 h

after transfection, cells were collected, diluted to 1 cell/100 µl and transferred to a 96-well plate at 100

697 μl/well for clonal selection. Correct clones were confirmed by Sanger sequencing of genomic DNA.

#### Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

## 698 Western blotting

- 699 Lysates of 293T cell lines were mixed with RIPA lysis buffer and 4X Laemmli buffer to obtain a 700 concentration of 1 µg/µl protein. Samples were incubated at 96°C for 5 minutes. 20 µl of each sample 701 was loaded onto a 10% SDS page gel. Proteins were separated by electrophoresis, transferred with a 702 semi-dry method onto a nitrocellulose membrane (Whatman, GE Healthcare), blocked at room 703 temperature for 2 hours with buffer A (5% skimmed milk, 1.2% w/v Tris-base, 9% w/v NaCl, 0.2% 704 Tween 20, pH 7.6), incubated with primary antibodies dissolved in buffer A overnight at 4°C, and 705 detected using secondary antibodies in buffer A. Primary antibodies used were probing for the 706 following proteins: MMUT (Abcam, ab67869, 1:1000, host: mouse), OGDH (Atlas antibodies, 707 HPA020347, 1:500, host: rabbit), GLUD (Abcam, ab166618, 1:2000, host: rabbit), Beta-actin (Sigma, 708 A1978, 1:5000, host: mouse). Secondary antibodies used were Anti-rabbit HRP (Santa Cruz, sc-2357,
- 709 1:5000, host: mouse), Anti-mouse HRP (Santa Cruz, sc-516102, 1:5000, host: goat).

#### 710 MMUT enzyme activity assay

711 Confluent cells from a T75 were detached using trypsin, the cell suspension centrifuged at 250 g, the 712 pellet washed two-times 1 mL in PBS and the supernatant discarded. Homogenates were obtained by 713 resuspension of cell pellets in 150  $\mu$ L of 5 mM KH<sub>2</sub>PO<sub>4</sub> (pH 7.4) followed by sonication on ice with 2 714 pulses for 15 seconds using the microprobe of an XL-2000 (Microson, Qsonica, Newtown, CT, USA) 715 with amplitude set to 2 microns. The homogenate was then diluted 1:4 in a final concentration of 50 716 µM adenosylcobalamin (Sigma C0884), 1 mM methylmalonyl-CoA (Sigma M1762) and 0.1 M assay 717 buffer KH<sub>2</sub>PO<sub>4</sub>. The enzymatic reaction was performed at 37°C for 30 min. Subsequently, the reaction 718 was stopped, and succinyl-CoA hydrolysed by addition of 500 mM KOH and incubation at 37°C for 719 15 min. The assay mixture was neutralized with  $HClO_4$  at a final concentration of 400 mM, the 720 sample centrifuged at 16,000 g and the supernatant discarded. Precipitates were frozen at -20 degrees 721 until further analysis. For mass spectrometry, the MMUT-KO sample was diluted 1:2, the WT sample 722 was diluted 1:50 in a dilution solution (Recipe, MS5021) and then precipitated with 4 parts 723 precipitation reagent with internal standard (Recipe, MS5112). After centrifugation (5min, 16'000 g)

Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

the supernatant was transferred into a fresh vial. Final succinate determination was performed by

HPLC separation and electrospray tandem mass spectrometry (ESI-MS/MS) detection (SCIEX

- 726 TripleQuad 5500 LC-MS/MS System).
- 727 KGDH enzyme activity assays

Assay of oxoglutarate dehydrogenase enzyme activity was performed in 293T cell clones according to

the manufacturer's instructions (Sigma-Aldrich, St. Louis, USA, catalogue number MAK189) using

- 730 the plate reader Victor Nivo by PerkinElmer.
- 731 Glutamine tracing studies

732 293T cells were cultured on coverslips in DMEM (Gibco, catalog number: 11960044) without L-

733 glutamine, sodium pyruvate and HEPES supplemented with 10% FBS, 1% antibiotic-antimycotic

(Gibco), and [U-<sup>13</sup>C]glutamine (final concentration 4 mM) (Sigma-Aldrich, catalog number: 605166)

for 4 hours. Medium was then removed, coverslips were quickly dipped into sterile double-distilled

vater at 37°C and quenched in 80% methanol at -80°C. Cells were scrapped in methanol, collected,

and centrifuged at 15'000 g for 15 minutes at 4°C. Supernatants were collected, snap frozen in liquid

738 nitrogen, and stored at -80°C prior to LC/MS analysis.

739 300 μl of sample was lyophilized overnight until dry and resolubilized in 200 μl loading buffer

740 (water, 0.5% formic acid) in narrow-bottom 96-deep well plates on shaker (800 rpm, 15°C, 10 min)

for LC-MS injection. Metabolites were separated using a ACQUITY UPLC HSS T3 1.8 μm, 100 x

742 2.1 mm I.D. column (Waters, Massachusetts, US) and eluted using the following gradient from

solvent A (water, 5 mM ammonium formate, 0.1% formic acid) to solvent B (methanol, 5 mM

ammonium formate, 0.1% formic acid) as follows: 2 minutes at 0% B, 2-3.5 mins to 4% B, 3.5-10

745 mins to 45% B, 10-12 mins to 70% B, 12-13.5s min to 100% B, with a isocratic plateau at 100% B for

2 mins to 15.5 mins, and from 15.5-16.5 mins to 0%B. After each run the column was re-equilibrated

for 8 mins at 100% A with a constant flow rate of 0.4ml/min.

#### Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

748	Mass spectra were acquired using a heated electro-spray ionization (HESI) source of a Q-Exactive
749	high resolution, accurate mass spectrometer (Thermo Scientific, Waltham, MS, USA). Mass spectra
750	were recorded in positive and negative mode with the MS detector in full-scan mode (Full-MS) in the
751	scan-range 50 to 750 m/z with an automatic gain control target of 1e6, an Orbitrap resolution of
752	70,000, and a maximum injection time of 80 ms. Peaks were integrated with Xcalibur (version
753	4.0.27.19, Thermo Fisher Scientific) using windows of 0.01 m/z and 20 seconds for retention time as
754	previously determined using a library of standards.

- HESI parameters: sheath gas flow rate 35 arbitrary units (AU), auxiliary gas flow rate 35 AU, sweep
- 756 gas flow rate 2 AU, spray voltage 3.5 kV, capillary temperature 350°C, aux gas heater temperature
- 757 350°C. Detector settings for full MS: In-source CID 0.0 eV, μscans = 1, resolution = 70,000, AGC
- target 1e6, max IT = 35 ms, spectrum data type, profile. Integration parameters: ICIS Peak
- 759 Integration, nearest RT, smoothing points 3, baseline window 40, area noise factor 3, peak noise
- 760 factor 70, minimum peak height 3.0.
- 761 Data preprocessing included missing value imputation and normalization to internal standards [<sup>2</sup>H]<sub>3</sub>-
- 762 creatine and [<sup>2</sup>H]<sub>4</sub>-citric acid for positive and negative mode respectively.

## 763 Affinity capture mass spectrometry

- 764 293T cells (ATCC #CRL-3216; Manassas, WV) were grown in Dulbecco's Modified Eagle Medium
- 765 (Gibco, Carlsbad, CA) supplemented with 10% fetal bovine serum (Gibco) and antibiotics (GE
- 766 Healthcare). Transient transfection of pCDNA3-C-Flag-LIC constructs was performed using
- 767 Lipofectamine 3000 (Thermo Fisher Scientific) according to manufacturer's instructions. 48 h after
- transfection, cells were crosslinked using 0.5% paraformaldehyde (PFA, Sigma-Aldrich) in PBS
- 769 (Gibco) for 10 min at RT, the reaction was quenched with 1.25 M glycine/PBS (Sigma-Aldrich) for
- 10 min at 4°C, cells were centrifuged for 5 min at 2,000×g at 4°C, and the pellet resuspended in lysis
- buffer (1% Nonidet P-40, 0.5% deoxycholine, 150 mM NaCl, 50 mM Tris-HCl, pH7.5, all Sigma-
- Aldrich). Pre-cleared cell extracts were immunoprecipitated with anti-flag M2 (F3165, Sigma-
- Aldrich) using Dynabeads Protein G (Thermo Fisher Scientific) according to the manufacturer's

#### Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

- 774 instructions. Following washing, peptides were released by trypsin (100 ng/ $\mu$ l in 10 mM HCl) and 775 supernatants collected, dried, dissolved in 0.1% formic acid. 776 All affinity-captured samples were measured on a Q Exactive mass spectrometer (Thermo Fisher 777 Scientific) with a MS1 resolution of 70,000 and an AGC target of 3e6 and a maximum injection time 778 of 100 ms over a scan range of m/z 350-1500. A data-dependent top 12 method was used for HCD 779 MS/MS with a normalized collision energy of 25 at a resolution of 35,000. Precursor ions were 780 isolated in a 1.2-Th window with an AGC target value of 1e5 with a maximum injection time of 120 781 ms. Dynamic exclusion was set to 40s.
- 782 Samples were analyzed using Mascot (Matrix Science, London, UK; version 2.6.2) with the SwissProt
- database (download date 20190204) assuming trypsin with at maximum two miscleavages. Mascot
- was searched with a fragment ion mass tolerance of 0.030 Da and a parent ion tolerance of 10.0 PPM.
- 785 Oxidation of methionine was specified as a variable modification. Scaffold (version Scaffold\_5.1.2,
- 786 Proteome Software Inc., Portland, OR) was used to validate MS/MS based peptide and protein
- 787 identifications. Peptide identifications were accepted if they could be established at greater than
- 788 95.0% probability by the Scaffold Local FDR algorithm. Protein identifications were accepted if they
- could be established at greater than 99.0% probability and contained at least 2 identified peptides.

## 790 Data analysis

- 791 Data analysis was performed using R version 4.1.0. For the global data layer inspection we used the
- MOFA package version 1.3.1<sup>22</sup>, the MASS package version 7.3-54<sup>56</sup>, the fgsea package version
- 1.18.0<sup>57</sup>. Gene enrichment analysis was performed using gene sets downloaded from
- 794 <u>http://www.gsea-msigdb.org/gsea/msigdb/index.jsp</u> "MSigDB Collections" on 28 December 2020.
- 795 Circos including chord plots were created using the circlize package version 0.4.13<sup>58</sup>. The Uniprot
- portal was accessed on 24 February 2021 at 4 PM to scrape protein localization data. The code for all
- the analyses and generation of figures is hosted on a repository on the GitHub platform under
- 798 <u>https://github.com/pforny/MMAomics</u>.

#### Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

# 799 Genetic variant investigation approach

800 Short variant calling was carried out with GATK and Deep Variant algorithms, and annotated with annovar <sup>59</sup>. CNVs were called with CNVnator <sup>60</sup> with a bin size of 100 and standard parameters, and 801 annotated with AnnotSV<sup>61</sup>. Variation in the MMUT gene was investigated first. When no genetic 802 803 cause for the phenotype was identified with this approach (two inactivating/damaging events in 804 MMUT), other genes known to be involved in MMA (based on literature reports) were investigated as 805 a virtual gene panel. When no genetic cause was found in the two previous steps, genes highlighted by 806 mutational burden (genes harboring pathogenic variants across the cohort in an autosomal recessive 807 pattern in two or more individuals) were investigated. Finally, all samples and controls were used to run OUTRIDER<sup>19</sup>, and genes highlighted as expression outliers associated with phenotypes 808 809 overlapping MMA were analyzed to either confirm the identified damaging variants, or to further 810 explore damaging variation in them. 811 Variants were prioritized with the following approach: First, any coding variant (excluding 812 synonymous variants) with a GnomAD frequency across all represented populations <0.01, in 813 homozygosity or compound heterozygosity with another relevant variant, and supported by at least 814 two forward and two reverse reads and at least 8 reads coverage, were evaluated. Second, all variants categorized by the automatic application of the ACMG criteria <sup>62</sup> by InterVar <sup>63</sup>, or classified in 815 ClinVar<sup>64</sup> as "pathogenic" or "likely pathogenic", in homozygosity or compound heterozygosity with 816 817 another relevant variant, were considered and evaluated. Third, variants with a dbscSNV ADA or 818 dbscSNV RF scores >0.6 in the annovar annotation using the database prepared and described previously <sup>65</sup> were evaluated. 819

For CNVs, individuals with a single heterozygous variant or no variation in *MMUT* and the other
genes of interest were investigated for the presence of relevant CNVs that could explain their
phenotype <sup>59</sup>.

Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

## 824 **References**

- 1. Argmann, C. A., Houten, S. M., Zhu, J. & Schadt, E. E. A Next Generation Multiscale View of
  Inborn Errors of Metabolism. *Cell Metab* 23, 13–26 (2016).
- 827 2. Garrod, ArchibaldE. The Croonian Lectures ON INBORN ERRORS OF METABOLISM. The
- 828 *Lancet* **172**, 1–7 (1908).
- 829 3. Ferreira, C. R., Rahman, S., Keller, M. & Zschocke, J. An international classification of inherited
- 830 metabolic disorders (ICIMD). Journal of Inherited Metabolic Disease 44, 164–177 (2021).
- 4. Rahman, S. Mitochondrial disease in children. J Intern Med 287, 609–633 (2020).
- 5. Hirano, M., Emmanuele, V. & Quinzii, C. M. Emerging therapies for mitochondrial diseases.
- 833 *Essays Biochem* **62**, 467–481 (2018).
- 6. 100,000 Genomes Project Pilot Investigators *et al.* 100,000 Genomes Pilot on Rare-Disease
- B35 Diagnosis in Health Care Preliminary Report. *N Engl J Med* **385**, 1868–1880 (2021).
- 7. Palmer, E. E. *et al.* Diagnostic Yield of Whole Genome Sequencing After Nondiagnostic Exome
  Sequencing or Gene Panel in Developmental and Epileptic Encephalopathies. *Neurology* 96,
  e1770–e1782 (2021).
- 839 8. Schon, K. R. *et al.* Use of whole genome sequencing to determine genetic basis of suspected
- 840 mitochondrial disorders: cohort study. *BMJ* e066288 (2021) doi:10.1136/bmj-2021-066288.
- 841 9. Cummings, B. B. *et al.* Improving genetic diagnosis in Mendelian disease with transcriptome
  842 sequencing. *Sci Transl Med* 9, eaal5209 (2017).
- 843 10. Kremer, L. S. *et al.* Genetic diagnosis of Mendelian disorders via RNA sequencing. *Nat Commun*844 8, 15824 (2017).
- 845 11. Gonorazky, H. D. *et al.* Expanding the Boundaries of RNA Sequencing as a Diagnostic Tool for
  846 Rare Mendelian Disease. *Am J Hum Genet* 104, 466–483 (2019).
- 847 12. Frésard, L. *et al.* Identification of rare-disease genes using blood transcriptome sequencing and
  848 large control cohorts. *Nat Med* 25, 911–919 (2019).
- 849 13. Froese, D. S. & Gravel, R. A. Genetic disorders of vitamin B<sub>12</sub> metabolism: eight
- complementation groups--eight genes. *Expert Rev Mol Med* **12**, e37 (2010).

Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

- 14. Forny, P., Froese, D. S., Suormala, T., Yue, W. W. & Baumgartner, M. R. Functional
- 852 characterization and categorization of missense mutations that cause methylmalonyl-CoA mutase
- 853 (MUT) deficiency. *Hum Mutat* **35**, 1449–1458 (2014).
- 15. Froese, D. S. et al. Structures of the Human GTPase MMAA and Vitamin B12-dependent
- 855 Methylmalonyl-CoA Mutase and Insight into Their Complex Formation\*,. Journal of Biological
- 856 *Chemistry* **285**, 38204–38213 (2010).
- Ruetz, M. *et al.* Itaconyl-CoA forms a stable biradical in methylmalonyl-CoA mutase and derails
  its activity and repair. *Science* 366, 589–593 (2019).
- 17. Jost, M., Cracan, V., Hubbard, P. A., Banerjee, R. & Drennan, C. L. Visualization of a radical
- 860 B12 enzyme with its G-protein chaperone. *Proc Natl Acad Sci U S A* **112**, 2419–2424 (2015).
- 18. Froese, S. & Baumgartner, M. R. Lysosomal Vitamin B12 Trafficking. in *Ion and Molecule Transport in Lysosomes* (CRC Press, 2020).
- 863 19. Brechtmann, F. *et al.* OUTRIDER: A Statistical Method for Detecting Aberrantly Expressed
- 864 Genes in RNA Sequencing Data. *The American Journal of Human Genetics* 103, 907–917
  865 (2018).
- 866 20. Forny, P. *et al.* Guidelines for the diagnosis and management of methylmalonic acidaemia and
   867 propionic acidaemia: First revision. *Journal of Inherited Metabolic Disease* 44, 566–592 (2021).
- 868 21. Hörster, F. *et al.* Prediction of outcome in isolated methylmalonic acidurias: combined use of
  869 clinical and biochemical parameters. *Journal of Inherited Metabolic Disease* 32, 630 (2009).
- 870 22. Argelaguet, R. *et al.* Multi-Omics Factor Analysis-a framework for unsupervised integration of
  871 multi-omics data sets. *Mol Syst Biol* 14, e8124 (2018).
- 872 23. Forny, P. *et al.* Novel Mouse Models of Methylmalonic Aciduria Recapitulate Phenotypic Traits
  873 with a Genetic Dosage Effect. *J Biol Chem* 291, 20563–20573 (2016).
- 24. Lamparter, D., Marbach, D., Rueedi, R., Bergmann, S. & Kutalik, Z. Genome-Wide Association
- 875 between Transcription Factor Expression and Chromatin Accessibility Reveals Regulators of
- 876 Chromatin Accessibility. *PLOS Computational Biology* **13**, e1005311 (2017).
- 877 25. Rath, S. et al. MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle
- localization and pathway annotations. *Nucleic Acids Res* **49**, D1541–D1547 (2021).

Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

- 879 26. Nusinow, D. P. et al. Quantitative Proteomics of the Cancer Cell Line Encyclopedia. Cell 180,
- 880 387-402.e16 (2020).
- 881 27. Williams, E. G. *et al.* Systems proteomics of liver mitochondria function. *Science* 352, aad0189–
  882 aad0189 (2016).
- 28. Heusel, M. *et al.* Complex-centric proteome profiling by SEC-SWATH-MS. *Mol Syst Biol* 15,
- 884 e8438 (2019).
- 29. Buescher, J. M. *et al.* A roadmap for interpreting (13)C metabolite labeling patterns from cells.
- 886 *Curr Opin Biotechnol* **34**, 189–201 (2015).
- 887 30. Chen, Q. et al. Rewiring of Glutamine Metabolism Is a Bioenergetic Adaptation of Human Cells
- with Mitochondrial DNA Mutations. *Cell Metabolism* 27, 1007-1025.e5 (2018).
- 889 31. Zhang, J. et al. 13C isotope-assisted methods for quantifying glutamine metabolism in cancer
- 890 cells. *Methods Enzymol* **542**, 369–389 (2014).
- 891 32. Liu, A. *et al.* From expression footprints to causal pathways: contextualizing large signaling
  892 networks with CARNIVAL. *npj Syst Biol Appl* 5, 1–10 (2019).
- 33. Lewis, J. E., Forshaw, T. E., Boothman, D. A., Furdui, C. M. & Kemp, M. L. Personalized
- 894 Genome-Scale Metabolic Models Identify Targets of Redox Metabolism in Radiation-Resistant
- 895 Tumors. *Cell Systems* **12**, 68-81.e11 (2021).
- 896 34. Wang, H. *et al.* Genome-scale metabolic network reconstruction of model animals as a platform
  897 for translational research. *PNAS* 118, (2021).
- 898 35. Sloan, J. L. *et al.* Exome sequencing identifies ACSF3 as a cause of combined malonic and
  899 methylmalonic aciduria. *Nat Genet* 43, 883–886 (2011).
- 36. Karczewski, K. J. & Snyder, M. P. Integrative omics for health and disease. *Nat Rev Genet* 19, 299–310 (2018).
- 902 37. Vockley, J. et al. Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation
- 903 disorders: Results from an open-label, long-term extension study. *J Inherit Metab Dis* 44, 253–
  904 263 (2021).
- 905 38. Longo, N. *et al.* Anaplerotic therapy in propionic acidemia. *Mol Genet Metab* **122**, 51–59 (2017).

Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

- 906 39. Willard, H. F., Ambani, L. M., Hart, A. C., Mahoney, M. J. & Rosenberg, L. E. Rapid prenatal
- 907 and postnatal detection of inborn errors of propionate, methylmalonate, and cobalamin
- 908 metabolism: a sensitive assay using cultured cells. *Hum Genet* **34**, 277–283 (1976).
- 40. Baumgartner, R. Activity of the cobalamin-dependent methylmalonyl-CoA mutase. The
- 910 Cobalamins: Methods in Hematology. Churchill Livingstone, Edinburgh, New York 181–195
- 911 (1983).
- 41. Causey, A. G. & Bartlett, K. A radio-HPLC assay for the measurement of methylmalonyl-CoA
  mutase. *Clinica Chimica Acta* 139, 179–186 (1984).
- 914 42. Eng, J. K., McCormack, A. L. & Yates, J. R. An approach to correlate tandem mass spectral data
- 915 of peptides with amino acid sequences in a protein database. *J Am Soc Mass Spectrom* **5**, 976–989
- 916 (1994).
- 917 43. Dorfer, V. *et al.* MS Amanda, a universal identification algorithm optimized for high accuracy
  918 tandem mass spectra. *J Proteome Res* 13, 3679–3684 (2014).
- 44. Brosch, M., Yu, L., Hubbard, T. & Choudhary, J. Accurate and sensitive peptide identification
  with Mascot Percolator. *J Proteome Res* 8, 3176–3181 (2009).
- 45. Xuan, Y. *et al.* Standardization and harmonization of distributed multi-center proteotype analysis
- supporting precision medicine studies. *Nat Commun* **11**, 5248 (2020).
- 46. McKenna, A. *et al.* The Genome Analysis Toolkit: a MapReduce framework for analyzing nextgeneration DNA sequencing data. *Genome Res* 20, 1297–1303 (2010).
- 47. Poplin, R. *et al.* A universal SNP and small-indel variant caller using deep neural networks. *Nat Biotechnol* 36, 983–987 (2018).
- 927 48. Fuhrer, T., Heer, D., Begemann, B. & Zamboni, N. High-throughput, accurate mass metabolome
- profiling of cellular extracts by flow injection-time-of-flight mass spectrometry. *Anal Chem* 83,
  7074–7080 (2011).
- 49. Want, E. J. *et al.* Global metabolic profiling of animal and human tissues via UPLC-MS. *Nat*
- 931 *Protoc* **8**, 17–32 (2013).
- 932 50. Abela, L. *et al.* Plasma metabolomics reveals a diagnostic metabolic fingerprint for mitochondrial
- aconitase (ACO2) deficiency. *PLoS One* **12**, e0176363 (2017).

Anaplerotic insufficiency in MMA

Manuscript – Forny et al.

- 934 51. Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y. & Morishima, K. KEGG: new perspectives on
- genomes, pathways, diseases and drugs. *Nucleic Acids Res* **45**, D353–D361 (2017).
- 936 52. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
- 937 53. Liao, Y., Smyth, G. K. & Shi, W. The Subread aligner: fast, accurate and scalable read mapping
- 938 by seed-and-vote. *Nucleic Acids Res* **41**, e108 (2013).
- 54. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8, 2281–2308
- 940 (2013).
- 55. Arbab, M., Srinivasan, S., Hashimoto, T., Geijsen, N. & Sherwood, R. I. Cloning-free CRISPR. *Stem Cell Reports* 5, 908–917 (2015).
- 943 56. Venables, W. N. & Ripley, B. D. Modern applied statistics with S. (Springer, 2002).
- 944 57. Korotkevich, G. et al. Fast gene set enrichment analysis. 060012
- 945 https://www.biorxiv.org/content/10.1101/060012v3 (2021) doi:10.1101/060012.
- 58. Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize Implements and enhances circular
  visualization in R. *Bioinformatics* 30, 2811–2812 (2014).
- 948 59. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from

high-throughput sequencing data. *Nucleic Acids Res* **38**, e164 (2010).

- 950 60. Abyzov, A., Urban, A. E., Snyder, M. & Gerstein, M. CNVnator: an approach to discover,
- genotype, and characterize typical and atypical CNVs from family and population genome
- 952 sequencing. *Genome Res* **21**, 974–984 (2011).
- 953 61. Geoffroy, V. et al. AnnotSV: an integrated tool for structural variations annotation.
- 954 *Bioinformatics* **34**, 3572–3574 (2018).
- 955 62. Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint
- 956 consensus recommendation of the American College of Medical Genetics and Genomics and the
- Association for Molecular Pathology. *Genet Med* **17**, 405–424 (2015).
- 958 63. Li, Q. & Wang, K. InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-
- 959 AMP Guidelines. *Am J Hum Genet* **100**, 267–280 (2017).
- 960 64. Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting
- 961 evidence. *Nucleic Acids Res* **46**, D1062–D1067 (2018).

Anaplerotic insufficiency in MMA

Manuscript - Forny et al.

- 962 65. Jian, X., Boerwinkle, E. & Liu, X. In silico prediction of splice-altering single nucleotide
- 963 variants in the human genome. *Nucleic Acids Res* **42**, 13534–13544 (2014).